Probiotics in asthma: immunoregulatory mechanisms and emerging opportunities for respiratory delivery—a narrative review Authors: Xiaocheng Wu, Yicheng Xie, Yingshuo Wang, Jiani Shan, Jiayao Song, Zhiyuan Lin, Rongrong Pan, Xin Yang Published: 2026 ABSTRACT AbstractBackground and ObjectiveAsthma is a complex heterogeneous respiratory disease influenced by various factors such as genetics, immunity, and environment. Probiotics and related microbial preparations can be used in the prevention and treatment of asthma. This review aims to clarify the role and mechanism of microbial preparations in the treatment of asthma through respiratory administration, as well as the theoretical basis as delivery carriers. This may provide new insights for the prevention and treatment of asthma.MethodsThis study employed the narrative review method and searched for articles published on PubMed between January 2007 and February 2026. The search terms included asthma, probiotics, airway microbiota, respiratory administration and nanoparticles. The inclusion criteria covered relevant original research, reviews, and guidelines, while editorials and articles lacking full text were excluded.Key Content and FindingsAlterations in airway microbiota are closely associated with the occurrence of asthma. Animal studies have demonstrated that oral intake of probiotics can effectively alleviate asthma symptoms, but their clinical application remains controversial. The main reasons include differences in study populations, asthma phenotypes, probiotic strains, dosages and treatment courses. The therapeutic effects and mechanisms of probiotic respiratory administration for asthma have been confirmed in animal experiments. Probiotics as delivery vehicles for respiratory administration in the treatment of asthma are theoretically feasible.ConclusionsProbiotics respiratory administration represents a potentially promising strategy to treat asthma. Probiotics as delivery vehicles can also be used to deliver anti-asthma drugs. However, current evidence is predominantly preclinical, and further studies are needed to optimize delivery, ensure safety and product standardization, and confirm clinical efficacy before routine clinical application.Keywords: Asthma, probiotics, airway microbiota, respiratory administration, treatment Introduction Asthma is one of the most common respiratory diseases affecting both children and adults worldwide (1). Its clinical features are characterized by wheezing, shortness of breath, chest tightness, and coughing, while its pathological features mainly include persistent inflammation, airway hyperresponsiveness (AHR), and reversible airflow limitation (1,2). The occurrence and development of asthma are influenced by various factors including genetics, immune responses, and environmental factors. Environmental factors encompass external factors such as air pollutants, allergen exposure, tobacco exposure, as well as the internal microecological environment composed of microorganisms in the human body (3,4). The most directly related aspect of the human microbiota to asthma lies in the airway microbiota. Phased treatment is typically adopted in the treatment of asthma. Glucocorticoid and bronchodilator are the most commonly used drugs (5), but long-term use of glucocorticoid has the risk of adverse reactions, including diabetes, osteoporosis, hypertension, cardiovascular disease and immunosuppression, which may also affect the growth and development of children (6). The excessive use of bronchodilators can increase the acute exacerbation and mortality rates of asthma patients (7). Studies indicate that probiotics and related microbial preparations can alter the composition of the airway microbiota, thereby restoring the immune system imbalance in asthma patients or assisting in drug delivery and efficacy, and can be used in the prevention and treatment of asthma (8). This review discusses the role of microbial preparations in the occurrence and development of asthma and the feasibility of airway administration. We present this article in accordance with the Narrative Review reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0390/rc). Methods This study employed the narrative review method. We conducted a literature search using PubMed, starting in February 2026 and covering the period from January 2007 to February 2026, with a particular focus on studies published after 2018. Medical subject headings (MeSH) and free-text terms were used, including “asthma”, “probiotics”, “airway microbiota”, “respiratory administration”, and “nanoparticles”. The inclusion criteria were: studies related to probiotics in the treatment of asthma and probiotics respiratory administration (including original research, reviews, and guidelines). The exclusion criteria were: editorials, articles without full text, and publications in languages other than Chinese or English. The literature screening process was independently completed by three authors. Table 1 provides a detailed description of the search strategy. Table 1Search strategy summaryItemsSpecificationDate of searchBetween February 2026 and March 2026Databases searchedPubMedSearch terms used“Asthma”, “probiotics”, “airway microbiota”, “respiratory administration”, and “nanoparticles”TimeframeFrom January 2007 to February 2026Inclusion and exclusion criteriaInclusion criteria: studies related to probiotics in the treatment of asthma and probiotics respiratory administration; original research, reviews, and guidelines; articles published in English or Chinese; studies published between January 2007 and February 2026; full-text availableExclusion criteria: editorials and articles without full textSelection processThree authors searched the database to select the relevant articles for this narrative review Search strategy summary The role of probiotics in the occurrence and development of asthma Influence of respiratory microbiota on asthma The lower respiratory tract was previously considered to be sterile (9). However, subsequent studies have demonstrated the presence of microorganisms in the lower airways, leading to increased research on lower airway microbiota (9). The lower airway microbiota in healthy individuals has a relatively consistent composition: at the phylum level, the lower airway microbiota is mainly composed of Firmicutes, Actinobacteria, Proteobacteria, and Bacteroidetes; at the genus level, Streptococcus, Prevotella, and Haemophilus are predominant (9,10). Asthma results in chronic airway inflammation. Its occurrence is closely related to the composition and distribution of the airway microbiota. Studies have shown that at the phylum level, the abundance of Proteobacteria and Firmicutes in the lower airways of asthma patients increases compared to normal individuals, while the abundance of Bacteroidetes, Actinobacteria, and Clostridia decreases and is often associated with poorly controlled asthma (11-14). The abundance of Actinobacteria is negatively correlated with the expression of bronchial inflammation genes, indicating that Actinobacteria may have a protective effect (15). At the genus level, asthma patients show an increase in Streptococcus, Haemophilus, Moraxella, and Neisseria, which may exacerbate airway inflammation and worsen asthma (10,14,16,17). Conversely, Prevotella, Corynebacterium, and Lactobacillus exert a protective effect against airway inflammation (13,15,18). The occurrence of childhood asthma is related to the early-life composition of the airway microbiota. A birth cohort study from Australia found that colonization of the upper airways with Streptococcus in infants is positively correlated with asthma development at the age of 5 years (19). Another birth cohort study from the United States found that colonization of lactobacilli in the nasopharynx after respiratory syncytial virus infection in infants is associated with a reduced risk of wheezing disease at the age of 2 years (20). The composition of the airway microbiota also affects the control and severity of asthma. A recent systematic review and meta-analysis further confirmed that both airway and gut microbiota in asthma patients exhibit reproducible alterations characterized by enrichment of Proteobacteria and depletion of beneficial commensals, supporting a causal role of microbiome dysbiosis in asthma pathogenesis (21). A prospective study of asthma children in the United States showed that nasal microbiota dominated by Corynebacterium and Dolosigranulum leads to fewer asthma attacks and lower exacerbation risk compared to nasal microbiota dominated by Staphylococcus, Streptococcus, and Moraxella (22). Another study of asthma children in the United States showed that the nasal microbiota dominated by Moraxella has a higher risk of acute exacerbation of asthma, while the microbiota dominated by Streptococcus increases the risk of viral infection (23). Introduction of probiotics Probiotics were defined by the Food and Agriculture Organization of the United Nations in 2001 as “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” (13). Probiotics can maintain the integrity of the digestive and immune systems (24), play a role in inducing immune regulation, preventing physiological stress, inhibiting pathogens, regulating the microbial community, and improving the barrier function of the intestinal epithelium (25,26). Lactobacillus, Bifidobacterium, and yeast are the most commonly used probiotic species with good safety and efficacy (27). The classification, composition, physicochemical properties, and sources of commonly used probiotics are summarized as follows (Table 2) (24,25). Table 2The classification, composition, physicochemical properties, and sources of commonly used probioticsClassificationCompositionPhysicochemical propertiesSources Lactobacillus Lactobacillus acidophilus Gram-positive rod, microaerophilic, non-motile, non-spore-forming, optimal growth temperature 35–38 °CSmall intestine Lactobacillus casei Gram-positive rod, microaerophilic, non-motile, non-spore-forming, facultative heterotypic fermented lactoseOral cavity, intestinal tract, vagina of humans Lactobacillus rhamnosus Gram-positive rod, anaerobic, non-spore-forming, unable to utilize lactoseIntestinal tract of humans and animals Lactobacillus plantarum Gram-positive rod, homolactic fermentation (pH around 6.5), facultative anaerobic, non-motile, non-spore-formingVarious fermented foods Lactobacillus fermentum Gram-positive rod, heterofermentative, acid-tolerantIntestinal tract of humans Lactobacillus bulgaricus Gram-positive rod, facultative anaerobic, optimal growth temperature 44–45 °C, optimal growth pH 7.0–7.2Yogurt Bifidobacteria Bifidobacterium bifidum Gram-positive, non-motile, strictly anaerobicOral cavity, intestinal tract, vagina of humans and animals Bifidobacterium longum Bifidobacterium breve Bifidobacterium adolescentis Bifidobacterium animalis Other lactic acid bacteria Lactococcus lactis Gram-positive cocci, facultative anaerobe, non-capsulated, non-spore-forming, complex nutritional requirements, optimum growth temperature 30 °CDairy and plant products Streptococcus thermophilus Aerobic Gram-positive bacterium, homofermentative, acid and bile-resistantDairy Bacillus Bacillus subtilis Without capsule, peritrichous flagella, motile, Gram-positive bacterium, capable of forming endogenous resistant spores elliptical to rod-shaped, located in the center or slightly off-center of the cell bodySoil and decomposed organic matter Bacillus coagulans Gram-positive rod, terminal spores, non-flagellated, homofermentative lactic acid bacterium, optimum growth temperature 45–50 °C, optimal pH 6.6–7.0, facultative anaerobeSoil, fermented foods, and human intestinal tract Bacillus clausii Gram-positive rod, non-spore-forming, typical lateral flagella, strictly aerobic or facultative anaerobic, forms endospores, does not form filamentous bodiesSoil, fermented foods, and human intestinalYeast Saccharomyces boulardii Single-cell fungus, grows well at 37 °C, non-pathogenic and non-disseminatingPlants like lychee and mangosteen The classification, composition, physicochemical properties, and sources of commonly used probiotics Effects and mechanisms of oral probiotics on the occurrence and development of asthma In recent years, numerous studies have suggested that oral probiotics may potentially prevent the onset and progression of asthma. Animal experiments have revealed that oral administration of Lactobacillus reuteri M-16V can reduce eosinophil counts in bronchoalveolar lavage fluid (BALF) of asthmatic mice and decrease the expression of T helper type 2 (Th2) cytokines [interleukin (IL)-5 and IL-13] in lung tissues (28). Lactobacillus rhamnosus GR-1 can reduce the total number of inflammatory cells in the airways of birch pollen-induced asthmatic mice and decrease the level of IL-1β in lung tissues, thereby alleviating AHR (29). Bifidobacterium animalis subsp. lactis CCFM1274 can reduce the infiltration of inflammatory cells around blood vessels and bronchi in lung pathological sections of asthmatic mice, and decrease the level of ovalbumin (OVA) specific immunoglobulin E (sIgE) in serum (30). Recent evidence further demonstrated that probiotic intervention can restore Th17/regulatory T cell (Treg) balance and enhance microbial metabolite production, thereby suppressing allergic airway inflammation (31). However, the efficacy of oral probiotics for asthma remains controversial in clinical studies. A randomized controlled trial (RCT) in Italy found that children aged 6–12 years with asthma showed significant improvement in symptoms and significantly enhanced quality of life after 4 weeks of consuming a mixture of probiotic strains compared to the placebo group (32). Similarly, an RCT in Iran found that adult asthma patients who consumed a mixture of seven probiotics for eight weeks exhibited significantly increased peripheral blood Tregs, improved lung function, significantly elevated asthma control test scores, and improved quality of life, suggesting that probiotics can alleviate clinical symptoms and improve quality of life in asthma patients (33). Another RCT in Iran also showed that adding oral Saccharomyces boulardii to routine treatment for 3 months can significantly improve forced expiratory volume in 1 second (FEV1) and reduced serum levels of IL-5 and immunoglobulin E (IgE) compared to the placebo group (34). However, an RCT from the United States found that supplementation with Lactobacillus rhamnosus during the first 6 months after birth did not seem to prevent asthma onset at 2 years of age (35). Additionally, a 7-day randomized, double-blind, three-way crossover trial in Australia found no significant improvement in asthma control and airway inflammation with combined use of inulin and probiotics, while symptoms improved to some extent in asthma patients treated with inulin alone, indicating that oral probiotics may not necessarily ameliorate asthma (36). Overall, while animal data are supportive, clinical trials remain inconsistent. The main reasons include differences in study populations, asthma phenotypes, probiotic strains, dosages and treatment courses. Most existing trials have small sample sizes and adopt varying evaluation indicators. In addition, asthma is highly heterogeneous and confounding factors are difficult to control. In the future, large sample, multi center, high-quality clinical trials are required for verification. There has been considerable exploration into the intrinsic mechanisms by which probiotics administered via the gastrointestinal tract alleviate airway inflammation. Some studies propose that probiotics can alter gut microbiota and alleviate airway inflammation through the gut-lung axis (37). Lactobacillus rhamnosus GG, upon entering the intestine, can interact with intestinal epithelial cells (IECs) and immune-active cells via Toll-like receptors (TLRs), thereby stimulating the release of anti-inflammatory cytokines such as IL-10 and IL-27 by Tregs (38). Lactobacillus rhamnosus GG, Streptococcus thermophilus, and Lactobacillus plantarum MB452 can strengthen intestinal barrier function by increasing mucins, tight junction molecules, goblet cells, and Paneth cells. Through these mechanisms, they ensure internal balance, inhibit pathogen growth, regulate gut microbiota, and alleviate asthma via the gut-lung axis (39). Comparison between oral and respiratory administration of probiotics in asthma Although oral probiotics have demonstrated promising immunomodulatory effects in experimental asthma models, their clinical efficacy remains inconsistent. One important reason is that orally administered probiotics exert their effects indirectly through modulation of the gut microbiota and the gut-lung axis (9). After passing through the gastrointestinal tract, probiotics must survive gastric acid, bile salts, digestive enzymes, and competition from resident microbiota before influencing systemic immune responses. Consequently, substantial interindividual variability exists in probiotic colonization efficiency, microbial interactions, and host immune responsiveness, which may contribute to inconsistent clinical outcome (40). In contrast, respiratory administration delivers probiotics directly to the airway mucosa, the primary site of asthma pathology. This route allows probiotics or their bioactive components to interact more efficiently with airway epithelial cells, dendritic cells (DCs), alveolar macrophages, and other local immune cells, potentially resulting in faster and stronger immunomodulatory effects. Furthermore, respiratory administration may reduce losses associated with gastrointestinal transit and improve local bioavailability within the respiratory tract (41). However, respiratory administration is not necessarily superior because direct comparative evidence remains limited. Compared to the oral probiotic administration, respiratory administration is supported predominantly by preclinical studies, as discussed in the following sections, and may raises additional concerns, including airway irritation, bronchospasm, delivery efficiency, microbial persistence, and safety in susceptible or immunocompromised individuals. The role and mechanisms of probiotics in the treatment of asthma via respiratory administration In recent years, the emergence of the “airway microbiome” paradigm has shifted the conventional view of the respiratory tract from a passive target of immune responses to an active interface of host-microbiota crosstalk. Accumulating evidence from asthma models has demonstrated that airway administration of probiotics exerts pleiotropic immunomodulatory effects, concurrently modulating innate immunity, adaptive immunity, and epithelial barrier integrity. These interventions collectively mitigate key asthmatic phenotypes, including AHR, eosinophilic airway inflammation, and IgE-dependent allergic sensitization. The published studies from January 2007 to February 2026 on respiratory administration of probiotics or related microbial preparations in asthma and allergic airway inflammation are summarized in Table 3. Table 3Published preclinical studies of respiratory administration of probiotics or related microbial preparations in asthma and allergic airway inflammationStudySpecies and modelProbiotics preparationRout and timingKey findingsMain limitationsDebarry et al., 2007 (42)Mouse; OVA asthma modelAcinetobacter lwoffii F78/Lactococcus lactis G121Intranasal administration; before sensitizationSuppress Th2 response, enhance Th1 response, and prevent allergic asthma before stress onsetEnvironmental isolate included; preventive design; no established-disease treatment armPellaton et al., 2012 (43)Mouse; OVA asthma modelLactobacillus paracasei NCC2461Intranasal vs. oral; during sensitizationIntranasal administration induces Treg cells, reduces IgE levels, and alleviates inflammation, with superior efficacy compared to certain oral treatmentsPreventive design; therapeutic efficacy was not assessedSpacova et al., 2019 (44)Mouse; BP asthma modelLactobacillus rhamnosus GGIntranasal; before and during BP exposureReduce IL-5, IL-13, BALF inflammatory cells, and AHRPreventive protocol only; no post-onset treatmentLi et al., 2022 (45)Mouse; OVA asthma modelHKCB CGMCC0313-1 or live CBAerosol inhalation vs. oral; after asthma inductionAerosol inhalation of HKCB can restore the Th1/Th2 balance, ameliorated autophagy, and inhibited the NF-κB/NLRP3 inflammasome signaling pathway, with superior efficacy compared to oral HKCB administration, and oral live CB administrationHeat-killed bacteria are not live probiotics; single animal modelWu et al., 2022 (46)Mouse; OVA/LPS-induced allergic asthma with pneumoniaProbiotics (LA-5, GG, and BB-12) and prebiotics (FOS and GOS)Intranasal; during asthma inductionInhibits TLR4/NF-κB to alleviate pneumonia and asthma inflammationMixed asthma/pneumonia model and combined intervention prevented evaluation of strain-specific effectsYang et al., 2022 (47)Mouse; PM2.5-aggravated OVA-induced allergic asthmaLP33Intratracheal vs. oral; during allergen challengeBoth routs can reduce BALF inflammatory cells but shows limited Th2/IgE suppressionIntratracheal administration has limited clinical translatability and only modest superiority over oral treatmentSrutkova et al., 2023 (48)Mouse; OVA-induced allergic airway inflammationEPS derived from Lacticaseibacillus rhamnosus LOCK900Intranasal; before allergen challengeIntranasal EPS increased pulmonary IgA production, induced TGF-β1 and FoxP3+ Tregs, suppressed Th2 cytokine responses, and alleviated allergic airway inflammationEPS is a purified bacterial product rather than a live probiotic; only prophylactic efficacy was evaluated in a murine modelClinical trialsHumanNone publishedNone publishedNone publishedNone publishedStudies exclusively investigating respiratory infections without an asthma or allergic airway inflammation model were excluded and are discussed separately in the text as indirect mechanistic evidence. No peer-reviewed human clinical trial evaluating respiratory administration of probiotics or related microbial preparations for asthma was identified through the final literature search date. AHR, airway hyperresponsiveness; BALF, bronchoalveolar lavage fluid; BP, Birch pollen; CB, Clostridium butyricum; EPS, exopolysaccharide; FOS, fructo-oligosaccharides; GOS, galacto-oligosaccharides; HKCB, heat-killed Clostridium butyricum; IgA, immunoglobulin A; IgE, immunoglobulin E; IL, interleukin; LP33, Lactobacillus paracasei 33; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3; OVA, ovalbumin; TGF-β, transforming growth factor-β; Th1, T helper type 1; Th2, T helper type 2; TLR4, Toll-like receptor 4; Treg, regulatory T cell. Published preclinical studies of respiratory administration of probiotics or related microbial preparations in asthma and allergic airway inflammation Studies exclusively investigating respiratory infections without an asthma or allergic airway inflammation model were excluded and are discussed separately in the text as indirect mechanistic evidence. No peer-reviewed human clinical trial evaluating respiratory administration of probiotics or related microbial preparations for asthma was identified through the final literature search date. AHR, airway hyperresponsiveness; BALF, bronchoalveolar lavage fluid; BP, Birch pollen; CB, Clostridium butyricum; EPS, exopolysaccharide; FOS, fructo-oligosaccharides; GOS, galacto-oligosaccharides; HKCB, heat-killed Clostridium butyricum; IgA, immunoglobulin A; IgE, immunoglobulin E; IL, interleukin; LP33, Lactobacillus paracasei 33; LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3; OVA, ovalbumin; TGF-β, transforming growth factor-β; Th1, T helper type 1; Th2, T helper type 2; TLR4, Toll-like receptor 4; Treg, regulatory T cell. Effects of respiratory administered probiotics on innate immune responses Innate immune activation and abnormal signal pathway cascade are the initial driving factors of allergic airway inflammation in asthma, and pattern recognition receptors, downstream inflammatory pathways and innate immune cells are core regulatory targets of respiratory probiotics. Lipopolysaccharide (LPS), a classical TLR4 ligand, and OVA, a commonly used model allergen, are widely used in experimental mouse asthma models. In experimental asthma models, LPS activates TLR4/nuclear factor-κB (NF-κB) signaling, whereas OVA serves as a model allergen to induce allergic airway inflammation. TLR4/NF-κB activation transcriptionally upregulates NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), pro-IL-1β, and pro-IL-18. Subsequent assembly of the NLRP3 inflammasome activates caspase-1, leading to the proteolytic maturation of pro-IL-1β and pro-IL-18 into their biologically active forms, IL-1β and IL-18, and promote leukotriene and prostaglandin production, resulting in airway inflammatory cell infiltration, mucus secretion, and AHR. Probiotics can downregulate TLR4 gene expression, inhibit TLR4/NF-κB/NLRP3 pathway activation, and exert anti-asthmatic effects (43-47). In addition to suppressing the pro-inflammatory TLR4/NF-κB/NLRP3 signaling axis, probiotics can also modulate adaptive immune responses through the activation of DC-associated TLR signaling pathways. Probiotics can activate DCs through their microbe-associated molecular patterns (MAMPs) interacting with pattern recognition receptors (e.g., TLR) on DCs. Subsequently, DCs releases a series of cytokines and chemokines to exert effects. Among these, the most significant effect is that IL-12 induces the production of interferon-γ (IFN-γ), thereby elevating Th1 cytokine levels, reducing Th2 cytokine levels, promoting Th cell differentiation towards Th1, and alleviating symptoms of high Th2-type asthma (49). Moreover, DCs activation can also stimulate the production of regulatory cytokines (such as IL-10) and differentiation of Tregs, thereby inducing immune tolerance, alleviating AHR, and reducing Th2 cytokine levels (43,50). Macrophages also represent important innate immune effectors in allergic asthma, and emerging evidence suggests that probiotics may modulate macrophage polarization and inflammatory responses, although direct evidence for respiratory probiotic administration remains limited (51). This regulatory mechanism contributes to the restoration of immune homeostasis in allergic asthma. Effects of respiratory administered probiotics on adaptive immune homeostasis in asthma Beyond the modulation of innate immune signaling pathways, probiotics exert their therapeutic effects in asthma by regulating adaptive immune responses and restoring immune homeostasis. These effects are primarily mediated through the correction of Th2-dominant immunity, induction of immune tolerance, and modulation of other T-helper cell subsets involved in allergic airway inflammation. The imbalance between Th1 and Th2 responses is a hallmark of allergic asthma, characterized by excessive production of Th2-associated cytokines, including IL-4, IL-5, and IL-13, which promote IgE synthesis, eosinophilic inflammation, and AHR. Probiotic treatment has been shown to restore Th1/Th2 homeostasis by enhancing Th1-associated immune responses, particularly through increased IFN-γ production, while suppressing Th2 cytokine expression. Research has demonstrated that, in mouse asthma models, administering either Lactobacillus acidophilus G121 or Lactococcus lwoffii F78 intranasally for 10 days before sensitization significantly suppressed airway inflammation by promoting an immune deviation from Th2 to Th1 in the allergen-specific response (42). Intranasal administration of Lacticaseibacillus rhamnosus GG significantly reduced IL-5 and IL-13 levels in BALF (44). Similarly, treatment with Lacticaseibacillus paracasei 33 (LP33) decreased IL-4 production and serum IgE concentrations (39). In addition to restoring Th1/Th2 balance, probiotics promote the expansion and functional activity of Foxp3+ Tregs, which play a pivotal role in maintaining immune tolerance. Probiotics treatment significantly increased pulmonary CD4+CD25+Foxp3+ Tregs, suggesting that Treg expansion contributes to the probiotic’s anti-inflammatory effects (43,50). Intranasal administration of Lactobacillus paracasei NCC2461 induced pulmonary CD4+CD25+Foxp3+ Tregs and reduced allergen-sIgE production (43). Moreover, Srutkova et al. demonstrated that intranasal delivery of probiotic-derived EPS similarly enhanced pulmonary Foxp3+ Tregs while increasing transforming growth factor-β (TGF-β) and secretory immunoglobulin A (IgA), suggesting that microbial components alone may be sufficient to induce respiratory immune tolerance (48). Emerging evidence also suggests that probiotics may influence Th17-associated immune responses and IL-17 production, although evidence regarding respiratory probiotic administration remains limited (51). Regulatory effects of respiratory administered probiotics on airway epithelial barrier function Disruption of the airway epithelial barrier is increasingly recognized as a key contributor to asthma development and progression. Impaired epithelial integrity facilitates allergen penetration, amplifies immune activation, and promotes chronic airway inflammation and remodeling. Probiotics have been shown to restore epithelial barrier dysfunction, particularly in the gastrointestinal tract, primarily through modulating tight and adherens junction proteins, however, there are limited reports about their regulatory effects on airway epithelial barriers (50). Early studies have shown that oral administration of probiotics can reduce the permeability of the bronchoalveolar vascular barrier (52,53). Evidence from oral probiotic studies further supports the barrier-protective potential of probiotics, although these findings are indirect with respect to respiratory probiotic administration in asthma. Nasal Lactococcus lactis likewise prevented S. pneumoniae-induced lung barrier disruption (54). These findings provide indirect evidence that respiratory probiotics may preserve airway epithelial barrier integrity. In vitro, Pam3CysSK4 concentration-dependently enhanced Calu-3 barrier function and reduced permeability by upregulating claudin-1/ZO-1 and downregulating occludin (55). These findings provide supportive mechanistic evidence that activation of epithelial innate immune signaling can enhance tight-junction integrity. Furthermore, by suppressing Th2-driven inflammation, probiotics inhibit goblet cell hyperplasia and mucus hypersecretion, both of which contribute to airway obstruction in asthma (42). Restoration of epithelial homeostasis may also reduce airway remodeling and improve long-term airway function. In addition, airway epithelial cells release epithelial-derived cytokines (alarmins), including thymic stromal lymphopoietin (TSLP), IL-25, and IL-33, which initiate and amplify type 2 airway inflammation (56). Restoration of epithelial integrity by probiotics may indirectly attenuate these epithelial inflammatory signals, although direct evidence from respiratory probiotic administration remains limited. Therefore, enhancement of epithelial barrier function represents another important mechanism by which respiratory probiotic administration protects against asthma. Overall, respiratory administration of probiotics alleviates asthma through coordinated regulation of innate immunity, adaptive immunity, and airway epithelial barrier function. Probiotics suppress innate inflammatory signaling pathways such as TLR4/NF-κB/NLRP3, restore Th1/Th2 immune balance, induce Treg-mediated immune tolerance, and strengthen epithelial barrier integrity. These effects collectively reduce inflammatory cell infiltration, mucus production, serum IgE levels, and AHR, highlighting the potential of inhaled probiotic formulations as a novel therapeutic strategy for asthma. The mechanisms of probiotic respiratory administration in asthma treatment are illustrated in Figure 1. Mechanisms of probiotic respiratory administration in the treatment of asthma. Probiotics inhibit TLR4 receptor activation, thus suppressing the TLR4/NF-κB/NLRP3 pathway, leading to reduced production of pro-inflammatory factors such as IL-1β, IL-18, leukotrienes, and prostaglandins. They restore epithelial barrier function by regulating tight junctions and adherens junctions of airway epithelial cells, improve cellular autophagy, enhance IL-10, IL-12, and IFN-γ production through binding to TLRs on DCs, decrease IL-4, IL-13, and other Th2 cytokine production, restore Th1/Th2 immune balance, and induce immune tolerance. Figure was created with BioRender.com. DC, dendritic cell; IFN-γ, interferon-γ; IL, interleukin; LPS, lipopolysaccharide; LT, leukotriene; NF-κB, nuclear factor-κB; NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3; OVA, ovalbumin; PG, prostaglandin; Th1, T helper type 1; Th2, T helper type 2; TLR, Toll-like receptor; Treg, regulatory T cell. Despite these encouraging preclinical findings, no peer-reviewed human clinical trial evaluating respiratory administration of probiotics or related microbial preparations for asthma has been identified to date. Therefore, the current evidence is limited to animal studies, and the safety, optimal formulation, dosing regimen, and clinical efficacy of inhaled probiotic-based therapies remain to be established through well-designed clinical trials. Feasibility and prospects of microbiota preparations for respiratory administration in the treatment of asthma Formulation and respiratory delivery considerations Due to the safety and efficacy of probiotic applications, probiotic based drug delivery systems are receiving increasing attention. This may represent an economical and robust means of delivering large molecule drugs (57). Oral administration is the preferred route for probiotic drug delivery systems, with acid resistance being a key factor in the success of oral administration (57). Probiotic nanotechnology offers many advantages over simple probiotic use, including efficient encapsulation, targeted delivery, controlled release rates, and improved stability (57,58). Integration of multi-strain probiotics (MSP) into nanoparticles (MSPNPs) can enhance the viability and resistance of probiotics, enabling targeted release in the gastrointestinal tract. This approach is more effective than free MSP in restoring IEC tight junctions and beneficial gut microbiota (58). Nanoparticles (NPs) prepared from Lactobacillus rhamnosus modified with chitosan, hyaluronic acid, and ononin have stronger resistance to harsh environments compared to pure Lactobacillus rhamnosus. They can specifically target M1 macrophages and enhance their phagocytic ability. Due to their strong survival ability, they can reduce the colonization of pathogens, thereby treating bacterial pneumonia (59). These studies demonstrate the feasibility of engineering probiotic-based formulations for drug delivery. However, current evidence is mainly derived from oral administration or infectious disease models, and their application to respiratory diseases, including asthma, remains at an early stage. Respiratory drug delivery routes are suitable for various pharmaceutical formulations such as solutions, gels, sprays, suspensions, emulsions, liposomes, and micro/NPs (57). Among these, nasal sprays are the most commonly used in clinical practice. However, physiological and anatomical factors such as membrane permeability, pH, nasal blood flow, nasal enzymes, mucin secretion from goblet cells, and mucociliary clearance can affect the efficiency of respiratory drug delivery (57). A potential future strategy is to combine microbiota-based formulations with conventional anti-asthmatic therapies, including glucocorticoids, β2 receptor agonists, theophylline derivatives, or biologics, in engineered NP systems with airway epithelial-targeting ligands. Such an approach may facilitate epithelial uptake and improve local drug delivery. However, this concept remains theoretical for asthma and requires further experimental validation before clinical application. Engineered probiotics and probiotic-derived extracellular vesicles (EVs) Microbiota-based preparations include live microbial therapeutics, inactivated microbial preparations, probiotic-derived EVs, and NPs containing probiotics or microbial products. These preparations differ in their biological characteristics, mechanisms of action, and potential applications. EVs are a group of heterogeneous, cell-derived membrane structures, which can be classified into two categories: ectosomes and exosomes. EVs can contain numerous components of cells, including DNA, RNA, lipids, metabolites, as well as cytoplasmic and cell surface proteins (60). EVs themselves are natural NPs, and using EVs derived from probiotics as drug carriers to deliver anti-asthma medications can sometimes be more convenient than directly using probiotic-prepared NPs. Research has shown that exosome-like NPs derived from Lactobacillus rhamnosus GG can prevent alcoholic liver disease by modulating mouse intestinal miR194-FXR signaling (61). Reshaping probiotic-derived EVs by surface modification and CRISPR/Cas editing can make them easily absorbed by intestinal epithelium and entering the central nervous system (CNS) through the blood-brain barrier (BBB) (62). Using EVs as carriers allows high-dose antibiotics to enter the CNS, which can treat CNS infections caused by multidrug-resistant superbugs (62). EVs formulations have been developed for drug delivery in respiratory system diseases: Oral administration of EVs derived from Lactobacillus rhamnosus EHA2 can alleviate lung and intestinal damage in mice infected with influenza A virus by weakening pro-inflammatory IL-17 signal transduction (63). EVs derived from mouse somatic cells can carry anti-asthma medications, and due to their natural intrinsic cell-targeting properties and low immunogenicity, they may be more effective in asthma treatment compared to other NPs (64). Collectively, these studies support the potential of engineered probiotics and probiotic-derived EVs as future delivery platforms. However, evidence supporting their application in respiratory drug delivery for asthma remains limited and is largely based on preclinical studies. Safety, manufacturing, and regulatory challenges Compared to healthy individuals, asthmatic patients exhibit alterations in the airway microbiota structure and relative abundance of various bacterial groups (65), and specific airway microorganisms can influence the onset and progression of asthma. Therefore, the use of microbiota preparations for asthma treatment, controlling its occurrence and development, provides a new path for the treatment of asthma. Regarding the safety of probiotic use, oral probiotics have been widely used clinically with few reports of adverse events. However, there is still a lack of experience with probiotic administration via the respiratory tract, and further research is needed on the strains and doses of probiotics for respiratory administration. Inactivated microbial preparations and probiotic-derived EVs may avoid some concerns associated with live microorganisms, although their long-term safety and immunogenicity also require further investigation. Currently, industrial production of oral probiotics is relatively mature, and theoretically, it is also feasible to develop probiotics into nasal sprays or nebulized inhalation formulations. However, the regulatory requirements and manufacturing standards for respiratory microbiota-based therapeutics remain to be established. Compared to EVs derived from somatic cells, probiotic-derived EVs are less readily absorbed by the airway epithelium due to their heterogeneity (64). Therefore, strategies to improve their targeting and epithelial uptake remain an important research direction. The safety of probiotic-derived EVs as respiratory delivery vehicles depends not only on the safety of the probiotic source but also on the characteristics of the carried therapeutic agents. It is also important to determine the interactions between microbiota-derived carriers and the loaded drugs. In addition, research on how to economically and effectively prepare high-quality and stable probiotic NPs will be essential for future industrialization. Currently, EVs extraction mainly relies on differential centrifugation methods, which yield low quantities and are only suitable for experimental research (60). Developing more efficient extraction and purification methods and increasing EV production will therefore be essential for large-scale manufacturing. Priorities for clinical translation Although microbiota-based preparations have shown encouraging results in preclinical studies, several important issues should be addressed before clinical translation. Future studies should identify the optimal microbial strains or microbial products, establish standardized manufacturing procedures, improve respiratory delivery efficiency, and comprehensively evaluate long-term safety. In addition, comparative studies are needed to determine the respective advantages of live microbial therapeutics, inactivated microbial preparations, probiotic-derived EVs, and probiotic-containing NPs. Their interactions with currently approved asthma therapies should also be investigated. Well-designed animal studies followed by carefully conducted clinical trials will be essential to determine whether these microbiota-based respiratory delivery strategies can ultimately become feasible therapeutic options for asthma. Conclusions In summary, microbiota-based respiratory therapeutics represent a promising strategy for asthma treatment, but their clinical translation remains challenging. Several key challenges must be addressed before these approaches can be adopted in clinical practice, including the identification of optimal microbial formulations, optimization of delivery strategies and dosing regimens, evaluation of airway persistence and interactions with the resident microbiota, comprehensive safety assessment, and standardization of manufacturing and quality-control procedures. In addition, appropriate regulatory frameworks and well-designed early-phase clinical trials are essential to establish safety, tolerability, biological activity, and preliminary efficacy. Addressing these challenges will be critical for determining whether microbiota-based respiratory interventions can ultimately become a safe and effective therapeutic option for asthma management. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0390/rc Funding: This work was supported by the National Natural Science Foundation of China (No. 82000030 to X.Y.) and the Special Fund for the Incubation of Young Clinical Scientist, The Children’s Hospital of Zhejiang University School of Medicine (No. CHZJU2022YS005 to X.Y.). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0390/coif). The authors have no conflicts of interest to declare. References Available at https://tp.amegroups.com/article/view/10.21037/tp-2026-0390/prf Supplementary Materials The article’s supplementary files as